Stryker Co. (NYSE:SYK) Shares Purchased by Liberty Capital Management Inc.

Liberty Capital Management Inc. lifted its stake in shares of Stryker Co. (NYSE:SYK) by 9.2% in the fourth quarter, Holdings Channel reports. The firm owned 12,600 shares of the medical technology company’s stock after buying an additional 1,057 shares during the period. Liberty Capital Management Inc.’s holdings in Stryker were worth $4,537,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Dunhill Financial LLC increased its stake in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Stryker in the third quarter worth approximately $36,000. Activest Wealth Management purchased a new stake in shares of Stryker during the fourth quarter worth approximately $36,000. Crews Bank & Trust acquired a new position in Stryker in the 4th quarter valued at $39,000. Finally, Hara Capital LLC purchased a new position in Stryker in the 3rd quarter valued at $42,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 1.2 %

NYSE SYK opened at $391.42 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a market capitalization of $149.22 billion, a P/E ratio of 50.44, a PEG ratio of 2.98 and a beta of 0.96. The firm’s 50-day moving average is $377.23 and its two-hundred day moving average is $364.97. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 EPS. On average, sell-side analysts anticipate that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s payout ratio is presently 43.30%.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research reports. Wells Fargo & Company upped their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Robert W. Baird upped their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group raised their target price on shares of Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research note on Thursday, January 30th. Truist Financial upped their price target on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research report on Thursday, January 30th. Finally, Stifel Nicolaus lifted their price objective on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $419.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.